|
Terbutaline
resources
|
|
|
|
|
|
DRUG INFO
Terbutaline
Drug Name:
Terbutaline
Indication: For the prevention of and reversal of bronchospasm in patients 12 years of age and older with asthma and reversible bronchospasm associated with bronchitis and emphysema; For the management of preterm labor
Pharmacology: Terbutaline is a relatively selective beta2-adrenergic bronchodilator. Terbutaline is indicated for the relief of bronchospasm associated with chronic obstructive pulmonary disease. The pharmacologic effects of beta adrenergic agonist drugs, including Terbutaline, are at least in part attributable to stimulation through beta adrenergic receptors of intracellular adenyl cyclase, the enzyme which catalyzes the conversion of adenosine triphosphate (ATP) to cyclic- 3',5'- adenosine monophosphate (c-AMP). Increased c-AMP levels are associated with relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from cells, especially from mast cells.
Mechanism Of Action: The pharmacologic effects of Terbutaline are at least in part attributable to stimulation through beta-adrenergic receptors of intracellular adenyl cyclase, the enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic AMP. Increased cyclic AMP levels are associated with relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from cells, especially from mast cells.
Drug Category: Adrenergic beta-Agonists; Tocolytic Agents; Bronchodilator Agents; Sympathomimetic; ATC:R03AC03; ATC:R03CC03
Brand Names/Synonyms: Brethaire; Brethine; Brican; Bricanyl; Bricar; Bricaril; Bricyn; CHEMBANK743; KWD 2019; T2528; Terbutalin; Terbutalina [Dcit]; Terbutaline; Terbutaline Sulfate; Terbutalino [Inn-Spanish]; Terbutalinum [Inn-Latin]
Dosage Forms: METERED-DOSE (AEROSOL); POWDER; Tablets; IV Injection; Subcutaneous Injection
Absorption: Not Available
Interactions: Drug Interactions:
The concomitant use of Terbutaline with other sympathomimetic agents is not recommended, since the combined
effect on the cardiovascular system may be deleterious to the patient.
Monoamine Oxidase Inhibitors or Tricyclic Antidepressants:
Terbutaline should be administered with extreme caution to patients being treated with monoamine oxidase
inhibitors or tricyclic antidepressants, or within 2 weeks of discontinuation of such agents, since the
action of terbutaline on the vascular system may be potentiated.
Beta-Blockers:
Beta-adrenergic receptor blocking agents not only block the pulmonary effect of beta-agonists,
such as Terbutaline, but may produce severe bronchospasm in asthmatic patients. Therefore, patients with asthma
should not normally be treated with beta-blockers. However, under certain circumstances, e.g., as prophylaxis
after myocardial infarction, there may be no acceptable alternatives to the use of beta-adrenergic blocking
agents in patients with asthma. In this setting, cardioselective beta-blockers could be considered, although
they should be administered with caution.
Diuretics:
The ECG changes and/or hypokalemia that may result from the administration of nonpotassium-sparing
diuretics (such as loop or thiazide diuretics) can be acutely worsened by beta-agonists, especially when the
recommended dose of the beta-agonist is exceeded. Although the clinical significance of these effects is not
known, caution is advised in the coadministration of beta-agonists with nonpotassium-sparing diuretics.
Chemical IUPAC Name: 5-(1-hydroxy-2-tert-butylamino-ethyl)benzene-1,3-diol
Chemical Formula: C12H19NO3
Half Life: 5.5-5.9 hours
Drug Type: Approved Drug
# Accession No: APRD00589
CAS Registry Number: 23031-25-6
|
|
|
|
|
|
Terbutaline News
(When available)
Landmark Banff store closes Dec 29, 2005
Rocky Mountain Outlook, Banff’s Bricyn Lumber closed its doors last week after 21 years — yet another mom and pop operation to have left the Banff community in the past decade. ...
|
|
|
